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Context:  To  protect  troops  against  the  use  of  anthrax  as  a biological  weapon,  the  US  Department  of Defense
began  an  anthrax  vaccination  program  in 1998.  14  years  after  the  inception  of  the  vaccination  program,
there  is  no evidence  suggesting  vaccination  against  anthrax  carries  long-term  health  risks  for Active  Duty
Soldiers.
Objective: To  investigate  the  association  between  Anthrax  Vaccine  Adsorbed  (AVA) received  while  on
Active  Duty  and  subsequent  disability  determined  by the  Veterans  Benefits  Administration.
Design,  setting  and  participants:  Case–control  study  nested  in  the  cohort  of  all  Active  Duty personnel
known  to have  separated  from  the  US  Army  between  December  1, 1997  and  December  31, 2005.  Cases
were  ≥10%  disabled,  determined  either  by the  Army  prior  to  separation  (N  = 5846)  or by the  Veterans
Benefits  Administration  (VBA)  after  separation  (N  =  148,934).  Controls  (N =  937,705)  separated  from  the
Army  without  disability,  and were  not  receiving  pensions  from  the  VBA  as  of April  2007.  Data  were
from  the  Total  Army  Injury  and  Health  Outcomes  Database  and  the  VBA  Compensation  and  Pension  and
Benefits  database.
Main outcomes:  Disability  status  (yes/no);  for primary  disability,  percent  disabled  (≥  10%,  20%,  >20%)  and
type of  disability.
Results:  Vaccination  against  anthrax  was  four  times  more  likely  among  disabled  Veterans  with  hostile  fire
pay records  (HFP,  a  surrogate  for deployment).  Vaccinated  Soldiers  with  HFP  had  lower  odds  of  disability
separation  from  the  Army  0.89  (0.80,  0.98);  there  was  no  association  between  vaccine  and  receiving
Army  disability  benefits  among  those  without  HFP  (OR  = 1.05,  CI: 0.96,  1.14).  Vaccination  was  negatively
associated  with  receiving  VA  disability  benefits  for those  with  HFP  (OR  =  0.66,  CI: 0.65,  0.67),  but  there
was little  or  no  association  between  vaccine  and  receipt  of VA  disability  benefits  for  those  without  HFP
(OR  =  0.95,  CI:  0.93,  0.97).
Conclusions:  Risk  of  disability  separation  from  the  Army  and  receipt  of  disability  compensation  from  the
VA  were  not  increased  in  association  with  prior  exposure  to  AVA.  This  study  provides  evidence  that
vaccination  against  anthrax  is  not  associated  with  long  term  disability.
© 2012 Elsevier Ltd. All rights reserved.
Anthrax is a zoonotic disease caused by Bacillus anthracis that
may  affect humans who handle the hide or wool of grazing animals
or work with live animals. Because of its stability and virulence, the
low rate of natural immunity in humans, and the ease with which it
can be aerosolized and deployed as a weapon, the US Department
of Defense identified B. anthracis as a threat to US troops, and initi-
ated an anthrax vaccination program in 1998 [1–3] that prioritized
 Disclaimer: The opinions or assertions contained herein are the private views of
the  author(s) and are not to be construed as official or as reflecting the views of the
Army, the VBA Department of Veterans Affairs or the Department of Defense.
∗ Corresponding author. Tel.: +1 413 256 3556.
E-mail address: ssulsky@environcorp.com (S.I. Sulsky).
individuals about to be deployed to regions deemed to be at a higher
threat for exposure to weaponized anthrax [4].
The frequency and severity of immediate adverse events asso-
ciated with Anthrax Vaccine Adsorbed (AVA) are similar to those
associated with other adult vaccines, and no study has produced
evidence of increased risk of any lasting condition associated with
AVA [5–13]. In spite of its demonstrated safety and effectiveness,
worries about potential long term effects persist [3,14,15]. Stud-
ies restricted to Active Duty Soldiers have the benefit of providing
nearly complete data on both vaccination status and health out-
comes because they can be based on routinely collected health care
records from a relatively closed system, and thus are not subject
to selection bias. Adverse vaccine events may  be under-counted,
however, if either their recognition or development is delayed past
0264-410X/$ – see front matter ©  2012 Elsevier Ltd. All rights reserved.
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Table 1
Inclusion and exclusion criteria.
Criterion N Excluded N Remaining
US Army Active Duty between 12/1/1997
and 12/31/2005a
1,014,998
Invalid vaccination date (prior to 3/1998) 643 1,014,355
Age  at entry into Army <17 or >34 yearsb 1418 1,012,937
No  date of separation 0 1,012,937
Duration of service ≤ 91.3 daysc 40,775 972,162
Deceased prior to separation from service 21 972,141
Disability determined by both APDA and
VBAd
30,354 941,787
APDA Analysise 153,016 788,771
VBA  Analysisf 9928 931,859
a Study start and end dates.
b Suggests unreliable data.
c To exclude disability due to injuries sustained in basic combat training.
d APDA = Army Physical Disability Agency. VBA = Veteran’s Benefits Administra-
tion.
e Includes all controls and ADPA cases with complete information on relevant
covariates.
f Includes all controls and VBA cases with complete information on relevant
covariates.
the time of separation from Service, or if Soldiers choose not to
report potential problems. To address these limitations, we  con-
ducted a nested case–control study to determine if vaccination
against anthrax during Active Duty is associated with subsequent
receipt of disability compensation through the Veterans Benefits
Administration (VBA). Separated Service Members are entitled to
seek disability compensation, health and other benefits from the
VBA and the Veterans Health Administration. Disability compen-
sation may  be awarded for problems that manifest after military
service if the problem can be documented as having originated
during Service, or if an established association exists with a mil-
itary exposure, e.g., Agent Orange exposure and later development
of diabetes [16].
1. Methods
Data were obtained from the Total Army Injury and Health
Outcomes Database (TAIHOD), which links occupational and demo-
graphic data from the Defense Manpower Data Center (DMDC)
with information from the Army Physical Disability Agency (APDA),
among others, for all Active Duty US Army Soldiers [17]. Anthrax
vaccination data were obtained from the Military Vaccine (MIL-
VAX) Agency. The VBA identified individuals receiving disability
benefits, along with reason for and percentage disability, and death
dates for those who were deceased as of April 2007. The protocol for
this study was reviewed and approved by the Institutional Review
Boards of ENVIRON International Corporation, the Army Research
Institute of Environmental Medicine, the Army Medical Research
and Materiel Command and the Human Subjects Division of the
University of Washington.
The cohort consists of all Soldiers on Active Duty between
December 1, 1997 and February 1, 2005. For each individual, we
abstracted the earliest data available from up to 18 semi-annual
DMDC updates and retained the earliest and latest recorded dates
of entry into, and separation from, the Army. Follow-up began with
the date of entry into the Army or the start of the study, whichever
came last, and ended with separation from Service, first disabil-
ity finding by the APDA, death, or the end of the study, whichever
came first. Reasons for exclusions and counts of excluded Soldiers
are shown in Table 1.
We separately analyzed two case series: those who  received dis-
ability ratings ≥10% and were discharged from the Active Duty
Army after formal evaluation by the ADPA (“APDA cases”), and
those with disability ratings of ≥10% and receiving disability
compensation from the VBA (“VBA cases”) subsequent to discharge
from the Army in April 2007. Both case series were compared to the
same controls, allowing for direct comparison of determinants of
risk for each. Controls comprise Soldiers who  had separated from
Service, had never been evaluated for or granted disability by the
APDA during Active Duty and were alive and not receiving VBA
compensation on the data extraction date.
Disabilities were classified according to the Veterans Admin-
istration Schedule for Rating Disability (VASRD) by both the APDA
and the VBA, allowing all cases to be classified according to primary
reason for and percent disability, and body system affected. Mus-
culoskeletal disabilities were categorized according to likelihood
of being of traumatic or non-traumatic origin. Exposure status was
determined by receipt of at least one dose of AVA during Active
Duty, delivered between March 1998 and December 31, 2005.
1.1. Statistical methods
Data analyses were completed using SAS version 9.1 [18]. We
identified possible confounders separately for the two case–control
comparisons by identifying the covariates that were associated
with both exposure and outcome. We  used logistic regression anal-
ysis to estimate the odds of disability by AVA exposure and 95%
confidence intervals (95% CI) for each case series versus controls.
Initial two-term models included a vaccination indicator and each
covariate that caused ≥10% change in estimated odds of disabil-
ity with vaccination status. Each remaining covariate was  added
individually, and we  retained covariates that changed the vaccina-
tion estimate for the disability odds ratio ≥ 5%. Interactions were
identified by examining whether effect estimates differed across
strata defined by covariates. No statistical testing was used to iden-
tify interactions because the large number of observations leads
to a high likelihood of identifying small magnitude differences as
statistically significant. The goodness of fit of final multiple logis-
tic regression models was evaluated using the Hosmer–Lemeshow
Goodness of Fit test and discrimination was  evaluated with the
c-statistic.
2. Results
After applying inclusion and exclusion criteria (Table 1), there
were 782,925 controls, 148,934 VBA cases and 5846 APDA cases
eligible for analysis; the VBA and APDA cases were mutually exclu-
sive. We  excluded an additional 30,354 cases designated disabled
by both the ADPA and the VBA. These records would not be infor-
mative for identification of differences in cases identified by the
two  agencies, because they were identified by both. They also were
included as cases in a prior cohort study [19].
The proportion of vaccinated individuals was similar for the two
case series, but higher for the controls (Table 2). Each case series had
higher proportions of women compared to the controls. The VBA
cases compared to APDA cases and controls were more likely to be
Black, better educated, and to have achieved higher pay grade while
in service. VBA cases served about twice as long as controls, and
more than 2.5 times longer than APDA cases. Controls were more
likely to have received hostile fire pay, a marker for deployment,
than either the APDA or VBA cases. Controls were followed for a
mean (standard deviation) of 4.1 (2.7) years, APDA cases for 2.9
(2.1) years, and VBA cases for 3.9 (2.4) years (Table 2).
Within controls and each case group, AVA status varied by
covariates (Tables 3a and 3b). Among VBA cases and controls, a
higher proportion of men  were vaccinated versus unvaccinated,
while the reverse was true for women. Vaccination status among
VBA cases was also associated with longer duration of follow-
up, longer duration of service and pay grade, with higher ranking
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Table 2
Distribution of covariates by case and control status: mean and standard deviation
(SD) or percent.
n = 937,705 Controlsa
(n = 782,925)
APDA casesa
(n = 5846)
VBA casesa
(n = 148,934)
Vaccinated
Yes 46.1 34.2 36.0
No  53.9 65.8 64.0
Age  (years)
Mean (SD) 20.2 (3.0) 20.4 (3.2) 20.5 (3.3)
Gender
Men 84.4 79.3 80.7
Women  15.6 20.7 19.3
Race
White 62.6 67.8 57.0
Black 22.0 21.8 29.4
Hispanic 9.3 6.9 7.6
Other 6.2 4.4 6.1
Educationb
≤ High school 97.3 98.0 90.8
>  High school 2.7 2.0 9.2
Marital statusb
Married 32.0 65.5 42.2
Unmarried 68.0 34.5 57.8
Pay  gradeb
E1–E3 60.9 66.1 32.2
E4–E6 25.4 29.2 33.6
E7–E9 2.5 1.5 20.0
Officersc 11.3 3.3 14.2
Duration follow-up mean (years)
Mean (SD) 4.1 (2.7) 2.9 (2.1) 3.9 (2.4)
Years duration of service mean (years)b
Mean (SD) 7.3 (6.5) 5.7 (5.0) 13.7 (9.1)
Hostile fire pay
Ever 48.3 31.4 37.1
Never 51.8 68.7 62.9
Major command codeb
U.S. Army Forces
Command
23.8 26.9 29.7
Training and Doctrine 49.6 50.6 32.3
V  Corps (Europe) 5.0 4.9 5.7
Medical Command 4.8 4.9 6.4
8th  U.S. Army 3.2 2.9 4.1
U.S.  Army Pacific 2.2 2.1 2.9
Special Operations 1.5 1.5 2.5
Signal Command 0.8 0.9 1.5
Intelligence and security 0.7 0.5 1.4
Other 8.4 4.8 13.5
Year follow-up ended
<1999 6.9 13.3 11.7
1999 6.0 12.8 10.1
2000 6.0 12.0 10.3
2001 6.4 9.6 11.0
2002 5.8 7.3 10.2
2003 5.6 8.6 10.7
2004 6.4 11.3 14.4
2005 56.8 25.0 21.7
a VBA cases: Veterans receiving benefits from the Veterans Benefits Administra-
tion as of February 2007; APDA cases: Soldiers determined disabled during Active
Duty by the Army Physical Disability Agency; Controls: Veterans without disability
and with known date of separation from the Army. Case and control categories are
mutually exclusive.
b Assessed at the beginning of follow-up.
c E1–E9: enlisted pay grades. Officers includes Warrant and commissioned offi-
cers.
Table 3a
Distribution of covariates by vaccination status for VBA casesa and controlsb: mean
and standard deviation (SD) or percent.
A: VBA cases and controlsa,b
(n = 931,859)
Never vaccinated
(n = 517,333)
Vaccinated
(n = 414,526)
Age (years)
Mean (SD) 20.3 (3.1) 20.2 (3.0)
Gender
Men  81.0 87.3
Women  19.0 12.7
Race
White 63.1 59.9
Black 22.4 24.1
Hispanic 8.5 9.7
Other 6.0 6.3
Educationc
≤ High school 95.9 96.7
>  High school 4.1 3.3
Marital statusc
Married 37.5 34.5
Unmarried 62.5 65.5
Pay  gradec
E1–E3 54.9 58.0
E4–E6 26.4 27.1
E7–E9 6.8 3.4
Officersd 12.0 11.5
Duration of active duty follow-up (years)
Mean (SD) 3.1 (2.4) 5.3 (2.3)
Duration of service (years)c
Mean (SD) 7.8 (7.8) 8.9 (6.8)
Hostile fire pay
Ever 26.5 78.0
Never 73.5 22.0
Major command codec
U.S. Army Forces Command 23.7 26.0
Training and Doctrine 45.6 48.5
V  Corps (Europe) 5.1 5.1
Medical Command 6.1 3.7
8th U.S. Army 3.1 3.7
U.S. Army Pacific 2.7 1.7
Special Operations 1.4 2.0
Signal Command 1.0 0.8
Intelligence and Security 1.1 0.6
Other 10.2 7.9
Year follow-up ended
<1999 13.6 0.2
1999 10.2 2.2
2000 9.3 3.4
2001 9.5 4.2
2002 9.1 3.3
2003 7.1 5.6
2004 6.2 9.6
2005 35.0 71.4
a VBA cases: Veterans receiving benefits from the Veterans Benefits Administra-
tion as of February 2007.
b Veterans without disability and with known date of separation from the Army.
c Assessed at the beginning of follow-up.
d Includes Warrant and Commissioned officers.
enlisted personnel (E7–E9) least likely to have been vaccinated
prior to separation compared to officers, E4–E6 grade or E1–E3
grade. Seventy-eight percent of vaccinated versus 26.5% of unvacci-
nated Veterans had ever received hostile fire pay (HFP). Vaccination
status did not vary notably by age, race-ethnicity, educational
attainment or major command (Table 3a).  There were similar pat-
terns of prior vaccination among categories of APDA cases and
controls (Table 3b).
Receipt of hostile fire pay, a marker for deployment, is strongly
and inversely associated with receipt of disability benefits from
the VA and risk of disability separation from the Army (Table 4a).
Because of the policy that placed Soldiers deployed to high threat
locations at higher priority for vaccination against anthrax, there
is also a strong association between AVA exposure and receipt of
S.I. Sulsky et al. / Vaccine 30 (2012) 6150– 6156 6153
Table 3b
Distribution of covariates by vaccination status for APDA casesa and controlsb: mean
and standard deviation (SD) or percent.
APDA cases and controlsb
(n = 788,771)
Never vaccinated
(n = 425,796)
Vaccinated
(n = 362,975)
Age (years)
Mean (SD) 20.3 (3.0) 20.2 (3.0)
Gender
Men  81.4 87.9
Women 18.6 12.2
Race/ethnicity
White 64.5 60.5
Black 20.8 23.3
Hispanic 8.8 9.9
Other 6.0 6.3
Educationc
≤ High school 97.3 97.3
>  High school 2.7 2.7
Marital statusc
Married 32.0 32.1
Unmarried 68.0 67.9
Pay  gradec
E1–E3 61.3 60.4
E4–E6 24.7 26.3
E7–E9 3.0 1.8
Officers 11.0 11.4
Duration active duty follow-up (years)
Mean (SD) 3.0 (2.5) 5.4 (2.3)
Duration of service (years)
Mean (SD) 6.3 (6.6) 8.4 (6.3)
Hostile fire pay
Ever 27.6 79.8
Never 72.4 20.3
Major command codec
U.S. Army Forces Command 22.5 25.3
Training and Doctrine 49.5 49.8
V  Corps (Europe) 4.9 5.1
Medical Command 5.8 3.7
8th U.S. Army 2.9 3.6
U.S. Army Pacific 2.6 1.7
Special Operations 1.3 1.9
Signal Command 0.9 0.7
Intelligence and Security 0.9 0.5
Other 8.9 7.7
Year follow-up ended
<1999 12.7 0.2
1999 9.4 2.1
2000 8.7 3.0
2001 8.8 3.7
2002 8.6 2.7
2003 6.5 4.7
2004 5.5 7.6
2005 40.0 76.1
a APDA cases: Soldiers determined disabled during Active Duty by the Army Phys-
ical Disability Agency.
b Veterans without disability and with known date of separation from the Army.
c Assessed at the beginning of follow-up.
d Includes Warrant and Commissioned officers.
hostile fire pay (Table 4b). The proportion of persons vacci-
nated among those receiving hostile fire pay appears to increase
with more recent date of separation from military service
(Tables 4a and 4b). A similar trend is not apparent between recent
date of separation and probability of vaccination among persons
who did not receive hostile fire pay.
After adjustment for covariates, Veterans who had been vac-
cinated against anthrax had lower odds of later receiving VBA
benefits compared to those who had not been vaccinated (Table 5).
Odds of non-traumatic disabilities and disability ratings of ≥ 10%
and 20% were 5%, 4%, and 19% lower, respectively, among those
with a history of anthrax vaccination compared to those unvac-
cinated. The odds of musculoskeletal disability and ratings above
20% were not associated with prior vaccination among Veterans
receiving VBA benefits. There was  no association between prior vac-
cination against anthrax and odds of disability separation from the
Army, overall or due to musculoskeletal or non-traumatic causes.
Odds of being rated 20% disabled were lower among those with
prior vaccination, but other levels of disability (≥ 10%, >20%) were
not associated with vaccination status (Table 5).
Goodness of fit testing for the final models shown in Table 5
indicated differences between the VBA and APDA case series.
Using variables recorded during Active Duty provided a model
that discriminated well between VBA cases and controls (c = 0.73),
but showed statistically significant lack of fit (p < 0.001 for the
Hosmer–Lemeshow test). The final model for the APDA case series
had adequate fit (p = 0.38), and the c-statistic for discrimination
between cases and controls was 0.66.
To examine possible interactions, we  stratified logistic regres-
sion models by receipt of HFP (Table 6). Among those with no record
of HFP, AVA was  associated with a 5% overall lower odds of receiv-
ing VBA benefits after separation from the Army, but associations
varied depending on disability outcome. AVA was  positively asso-
ciated with odds of musculoskeletal and non-traumatic disabilities
and a ≥ 10% rating. Odds of more severe disability ratings were
slightly elevated and marginally statistically significant (Table 6).
In contrast, among Veterans receiving VBA disability benefits who
had received HFP while on Active Duty, the adjusted odds of disabil-
ity, overall and within any category of disability type or severity,
were reduced by 20% to nearly 40% among those vaccinated during
Active Duty (Table 6).
Prior anthrax vaccination was not associated overall with sepa-
ration from the Army for disability among Soldiers without HFP
records (APDA cases) (Table 6). The associations between prior
anthrax vaccination and odds of musculoskeletal disability, non-
traumatic disability, and a >20% disability rating were similarly not
significant. AVA was associated with lower odds of receiving an
ADPA disability rating of 20% but slightly higher odds of receiving a
10% disability rating. As was seen for the VBA analysis, Soldiers with
HFP and prior AVA had significantly lower odds of ADPA disability
for all categories except 10% ratings (Table 6).
The results in Table 6 were derived from models developed
individually for each of the strata using the methods previously
described; these led to different model covariates as described in
the footnotes to Table 6. The VBA cases-no HFP best fitting models
(Table 6) shows an overall lower risk of disability, while elevated
risks are seen when the outcome is subdivided into type or degree
of disability (musculoskeletal, non-traumatic, 10%, 20%, >20%). To
further explore these anomalous results, we re-ran these models
using the same covariates included in the overall (disability yes/no)
model (Table 6, same covariates as all disabilities model). In this
re-analysis, the odds ratios within each disability outcome stratum
were mainly in agreement, with a negative association between
AVA and the outcome seen in 9 of 10 comparisons, and a positive
association for musculoskeletal disability among those not receiv-
ing HFP. This was the smallest disability category and comprised
only 5% of all Veterans receiving VBA benefits.
3. Discussion
These analyses demonstrate no overall increase in risk of dis-
ability associated with AVA for cases identified by the Army (APDA
cases) or the VBA. The results for APDA case series are generally
consistent with those of a previous cohort analysis that included
up to six years of follow-up from first dose of AVA and showed no
contribution of anthrax vaccination to risk of APDA disability eval-
uation or separation from the Army [19]. The models predicting
receipt of VBA benefits show overall reduced risk for Veterans who
received AVA during Active Duty compared to those who did not.
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Table 4a
Hostile fire pay by year of separation from Service, disability.
A: VBA cases and controlsa,b Number of soldiers (%)
Ever received hostile fire pay Never received hostile fire pay
Date of separation Disabled Not disabled Disabled Not disabled
Up to 1999 1471 (18.5) 6467 (81.5) 15,493 (24.6) 47,510 (75.4)
1999–2000 2230 (20.0) 8944 (80.0) 12,732 (25.2) 37,779 (74.8)
2000–2001 3224 (23.0) 10,806 (77.0) 12,075 (25.0) 36,331 (75.0)
2001–2002 3848 (24.1) 12,132 (75.9) 12,348 (24.6) 37,932 (75.4)
2002–2003 4037(27.5) 10,643 (72.5) 11,197(24.2) 34,974 (75.8)
2003–2004 6153 (27.6) 16,180 (72.4) 9715 (25.9) 27,845 (74.1)
2004–2005 12,517 (31.9) 26,732 (68.1) 8993 (27.8) 23,309 (72.2)
2005–2006 12,367 (29.2) 29,950 (70.8) 6817 (26.3) 19,077 (73.7)
2006+  9394 (3.2) 283,273 (96.8) 4323 (4.6) 113,041 (96.3)
B:  APDA cases and controlsb,c
Up to 1999 29 (1.4) 6467 (98.6) 495 (1.0) 47,510 (90.0)
1999–2000 85 (1.0) 8944 (99.1) 674 (1.7) 37,779 (98.3)
2000–2001 132 (1.2) 10,806 (98.8) 585 (1.6) 36,331 (98.4)
2001–2002 124 (1.0) 12,132 (99.0) 456 (1.2) 37,932 (98.8)
2002–2003 96 (0.9) 10,643 (99.1) 339 (1.0) 34,974 (99.0)
2003–2004 141 (0.9) 16,180 (99.1) 300 (1.1) 27,845 (98.9)
2004–2005 204 (0.8) 26,732 (99.2) 374 (1.6) 23,309 (98.4)
2005–2006 505 (1.7) 29,950 (98.3) 463 (2.4) 19,077 (97.6)
2006+ 517 (0.2) 283,273 (99.8) 327 (0.3) 113,041 (99.7)
a VBA cases: Veterans receiving benefits from the Veterans Benefits Administration as of February 2007.
b Veterans without disability and with known date of separation from the Army.
c APDA cases: Soldiers determined disabled during Active Duty by the Army Physical Disability Agency.
The timing of disability determination and the case-defining cri-
teria used by the two agencies differ. The VBA grants benefits to
Veterans who have disabling conditions caused or worsened by
Servicea, whereas the APDA determines disability based on ability
to meet duty requirements. Two observations suggest these dif-
ferences in case ascertainment methods are meaningful: 1. The
association between AVA during Active Duty and subsequent dis-
ability status is null for APDA cases but negative for VBA cases;
and 2. Models using factors identified during Active Duty provided
adequate goodness of fit for the APDA analyses, but not the VBA
analyses. Discrimination was adequate for both models.
For both the VBA and APDA case series, receipt of HFP was asso-
ciated with a reduction in odds of disability. Among those without
HFP records, the results generally showed null associations or small
magnitude increases in odds of disability as determined by both the
VBA and the Army. Because there is no reason to expect AVA to have
different biological effects, i.e., raising the risk of disability for one
group and lowering the risk for the other group, the most plausible
interpretation of these results, given the overall negative associa-
tions between disability and AVA, is that they reflect selection or
other residual confounding. For example, deployed personnel were
subject to higher standards for health and fitness compared with
non-deployed Soldiers. We  suspect this “Healthy Warrior Effect”
[20] explains the lower risks of disability associated with vacci-
nation status for those who  enlisted prior to 2000 and for those
with HFP records [20]. The finding of a possible increase in muscu-
loskeletal outcomes among those who  did not receive HFP in both
the best fitting and same covariates models (Table 6) is unlikely:
Table 4b
Hostile fire pay by year of separation from Service, vaccination status.
A: VBA cases and controlsa,b Number of soldiers (%)
Ever  received hostile fire pay Never received hostile fire pay
Date of separation Vaccinated Not vaccinated Vaccinated Not vaccinated
Up to 1999 689 (8.7) 7249 (91.3) 287 (0.5) 62,716 (99.5)
1999–2000 3020 (27.0) 8154 (73.0) 5925 (11.7) 44,586 (88.3)
2000–2001 4574 (32.6) 9456 (67.4) 9581 (19.8) 38,825 (80.2)
2001–2002 5796 (36.3) 10,184 (63.7) 11,664 (23.2) 38,616 (76.8)
2002–2003 5182 (35.3) 9498 (64.7) 8619 (18.7) 37,552 (81.3)
2003–2004 13,469 (60.3) 8864 (39.7) 9605 (25.6) 27,995 (74.4)
2004–2005 31,888 (81.2) 7361 (18.8) 7669 (23.7) 24,633 (76.3)
2006–2006 36,263 (85.7) 6054 (14.3) 6179 (23.9) 19,715 (76.1)
2006+ 222,425 (76.0) 70,242 (24.0) 31,691 (27.0) 85,673 (73.0)
B:  APDA cases and controlsb,c
Up to 1999 599 (9.2) 5897 (90.8) 251 (0.5) 47,754 (99.5)
1999–2000 2469 (27.3) 6560 (72.7) 4952(12.9) 33,501 (87.1)
2000–2001 3577 (32.7) 7361 (67.3) 7424(20.1) 29,492 (79.9)
2001–2002 4563 (37.2) 7693 (62.8) 8810(23.0) 29,578 (77.0)
2002–2003 3808 (35.5) 6931 (64.5) 5835 (16.5) 29,478 (83.5)
2003–2004 10,060 (61.6) 6261 (38.4) 6716 (23.9) 21,429 (76.1)
2004–2005 22,421(83.5) 4515 (16.8) 4928 (20.8) 18,755 (79.2)
2006–2006 26,637 (87.5) 3818 (12.5) 4212(21.6) 15,328 (78.4)
2006+ 215,335(75.9) 68,455(24.1) 30,378(26.8) 82,990 (73.2)
a VBA cases: Veterans receiving benefits from the Veterans Benefits Administration as of February 2007.
b Veterans without disability and with known date of separation from the Army.
c APDA cases: Soldiers determined disabled during Active Duty by the Army Physical Disability Agency.
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Table 5
Case and control counts (percents) and adjusted odds ratios (95% confidence intervals) for disability.
N (%) OR (95% confidence interval)
VBA casesa
All disabilitiesb 148,934 0.79 (0.78–0.80)
Musculoskeletale,f 7351 0.98 (0.92, 1.04)
Non-traumatice,f 65,224 0.95 (0.93, 0.97)
Disability 10%e,f 90,584 (60.8d) 0.96 (0.94, 0.98)
Disability 20%e,f 21,154 (14.2d) 0.81 (0.79, 0.84)
Disability > 20%e,f 37,196 (25.0d) 0.98 (0.96, 1.01)
APDA casesa
All disabilitiesc 5846 0.98 (0.92, 1.05)
Musculoskeletale 3924 0.94 (0.87,1.02)
Non-traumatice 4693 0.94 (0.87, 1.01)
Disability 10%e 4140 (70.8) 1.05 (0.97, 1.14)
Disability 20%e 690 (11.8) 0.70 (0.57, 0.85)
Disability > 20%e 1016 (17.4) 0.91 (0.78, 1.06)
Controlsa 782,925 1.0
a VBA cases: Veterans receiving benefits from the Veterans Benefits Administration as of February 2007; APDA cases: Soldiers determined disabled during Active Duty
by  the Army Physical Disability Agency; Controls: Veterans without disability and with known date of separation from the Army. Case and control categories are mutually
exclusive.
b Adjusted for gender, age, race/ethnicity, duration of service, hostile fire pay, major command code, and ever served abroad (yes/no).
c Adjusted for gender, age, race/ethnicity, pay grade, hostile fire pay, major command code, and ever served abroad (yes/no).
d Percent of disabilities within category (column percent).
e Model does not include major command code.
f Based on primary reason for disability and Veteran’s System for Rating Disabilities code.
there was no positive association between musculoskeletal
disability and vaccination among subjects who did receive HFP, and
in fact the association in this group was significantly negative. The
plausibility of a causal association that is protective in one group
and not in the other is low. Furthermore, the number of sub-group
comparisons raises the likelihood of false positive associations in
either direction.
Most previous studies of adverse vaccine effects in the Mili-
tary evaluated the experiences of Active Duty personnel, which
constrained inquiry to short-term adverse events [8].  A subset of
those previous studies additionally employed data from passive
surveillance systems, which, while useful for generating hypothe-
ses, cannot be used to test whether reported adverse events are
associated with the purported exposure because of the high likeli-
hood of incomplete or biased case ascertainment [7].
To improve completeness and reduce the likelihood of biased
reporting, we  analyzed data originally collected for administra-
tive purposes by both the Army and the VBA. Two-thirds of the
cases included in this study were identified by the VBA but not the
APDA; finding cases in the VBA system may  thus provide a more
Table 6
Case and control counts (percents) and adjusteda odds ratios (95% confidence intervals) for disability, by receipt of hostile fire pay.
No hostile fire pay Hostile fire pay
N (%) Best fitting
models
Same covariates as
all disabilities
model
N (%) Best fitting
models
Same covariates as
all disabilities
model
OR  (95% confidence
interval)
OR (95% confidence
interval)b
OR (95% confidence
interval)
OR (95% confidence
interval)b
VBA casesa
All disabilitiesb 93,693 (62.9g) 0.95 (0.93, 0.97) 0.95 (0.93, 0.97) 55,241 (37.1g) 0.66 (0.65, 0.67) 0.66 (0.65, 0.67)
Musculoskeletale,f 5675 1.18 (1.10, 1.27) 1.23 (1.15, 1.33) 1676 0.73 (0.66, 0.80) 0.72 (0.65, 0.80)
Non-traumatice,f 40,769 1.07 (1.04, 1.10) 0.90 (0.88, 0.93) 24,455 0.81 (0.78, 0.83) 0.68 (0.66, 0.70)
Disability 10%e,f 56,029 (59.8d) 1.16 (1.13, 1.19) 0.97 (0.95, 1.00) 34,555 (67.6d) 0.78 (0.77, 0.80) 0.65 (0.63, 0.66)
Disability 20%e,f 14,120 (15.1d) 1.04 (0.99, 1.09) 0.86 (0.82, 0.90) 7034 (12.7 d) 0.62 (0.59, 0.65) 0.51 (0.49, 0.54)
Disability > 20%e,f 23,544 (25.1d) 1.04 (1.00, 1.08) 0.88 (0.85, 0.92) 13,652 (24.7d) 0.88 (0.85, 0.91) 0.76 (0.73, 0.79)
APDA  casesa
All disabilitiesc 4013 (68.6) 1.05 (0.96, 1.14) 1833 (31.4) 0.89 (0.80, 0.98)
Musculoskeletale 2772 1.06 (0.96, 1.18) 1152 0.81 (0.71, 0.91)
Non-traumatice 3308 1.01 (0.92, 1.11) 1385 0.83 (0.74, 0.93)
Disability 10%e 2865 (71.4) 1.12 (1.01, 1.23) 1275 (69.6) 0.97 (0.86, 1.09)
Disability 20%e 507 (12.6) 0.66 (0.50, 0.87) 183 (10.0) 0.72 (0.50, 0.98)
Disability > 20%e 641 (16.0) 1.11 (0.91, 1.37) 375 (20.4) 0.69 (0.56, 0.85)
Controlsa 377,798 (48.3c) 1.0 405,127 (51.7c) 1.0
a VBA cases: Veterans receiving benefits from the Veterans Benefits Administration as of February 2007; APDA cases: Soldiers determined disabled during Active Duty
by  the Army Physical Disability Agency; Controls: Veterans without disability and with known date of separation from the Army. Case and control categories are mutually
exclusive.
b Adjusted for gender, age, race/ethnicity, duration of service, major command code, and ever served abroad (yes/no).
c Adjusted for gender, age, race/ethnicity, pay grade, major command code, and ever served abroad (yes/no).
d Percent of disabilities within category (column percent).
e Model does not include major command code.
f Based on primary reason for disability and Veteran’s System for Rating Disabilities code.
g Percent with and without HFP (row percent).
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sensitive indicator, casting a “broader net” than using only APDA
data. We  hypothesized that disabilities identified in the VBA system
might additionally represent more severe or longer-lasting condi-
tions than those identified by the APDA, and indeed found a higher
proportion of VBA cases to be at least 20% disabled compared to
APDA cases (25% versus 16%). Because the VBA captures disability
ratings independent of choice or usage of health care facilities, it is
less likely that this study suffers from biased case finding or under-
reporting than if clinical contact in a particular health care system
had been required to capture outcomes.
Others have found that the likelihood of spontaneously report-
ing a potential vaccine-related adverse event is several-fold lower
in Military compared to civilian populations, and that both the
severity of the event and its likelihood of being causally associ-
ated with vaccine were higher for Military compared to civilian
vaccinates [21]. On the other hand, use of administrative data for
research purposes is associated with its own limitations. The VBA
file we used represents a “snapshot” of all veterans with a disabil-
ity rating and receiving compensation as of April 2007, 2.5 years
after the end of the study as originally designed. It was not possi-
ble to capture the dates on which disabilities were determined, so
we could not account for follow-up time. The VASRD codes used by
both the VBA and the APDA group outcomes into broad categories
of reasons for disability, potentially introducing error in choosing
which outcomes were plausibly related to AVA. It is also not pos-
sible to validate the reasons for disability assigned to individual
Veterans.
4. Conclusions
Using cases identified from both VBA and APDA files, we  found
no overall higher risk of objectively assessed disability status with
receipt of AVA. VBA data did not show any consistent statistically
significant associations between vaccine exposure and subsequent
disability, and for most comparisons showed lower odds of dis-
ability. AVA was  associated with reduced risk of overall disability
among those with HFP records and among VBA cases without HFP.
Among APDA cases without HFP, vaccination was associated with
a small non-significant increase in risk of disability overall, and a
statistically significant 12% higher odds of 10% disability and a 34%
lower odds of 20% disability, suggesting likely type 1 errors due
to multiple testing. There were also small magnitude increases in
odds of certain categories of disability associated with AVA for VBA
cases without HFP, although this appeared to be dependent on the
strategy used to build the regression models, with the same covari-
ates model showing mainly lower odds of disability depending on
the outcome stratum. Furthermore, the VBA model demonstrated
lack of fit. Statistically significant reductions in odds of disabil-
ity associated with vaccination among those with HFP records is
more likely due to selection bias (the “Healthy Warrior Effect”) aris-
ing from pre-deployment health screening than a true protective
effect. This study supports our previous analyses of Army disabil-
ity experiences, and provides additional evidence that the AVA is
not associated with adverse outcomes as captured by the VBA and
APDA databases.
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